Cyclo Therapeutics, Inc. (CYTHW) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Cyclo Therapeutics, Inc.
Address
6714 NW 16th Street
Gainesville, FL 32653
United States of America (the)
Phone
N/A
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8
First IPO Date
December 18, 2020
Key Executives
| Name | Title | Pay | Year Born |
| N. Scott Fine | Chief Executive Officer & Director | 569,919 | 1957 |
| Jeffrey L. Tate | Chief Operating Officer, Chief Quality Officer & Director | 255,138 | 1958 |
| Joshua Fine | Chief Financial Officer & Secretary | 421,174 | 1982 |
| Michael Eric Lisjak | Senior Vice President of Business Development & Chief Regulatory Officer | 430,402 | 1974 |
| Karen Mullen FFPM | Interim Chief Medical Officer | 0 | N/A |
| C. Strattan | Founder & Director | 0 | 1946 |
| Lori McKenna | Global Head of Patient Advocacy | 0 | N/A |
AD
Description
Cyclo Therapeutics, Inc. is dedicated to developing biopharmaceutical treatments derived from cyclodextrin to combat various illnesses. A central component of their research and development pipeline is Trappsol Cyclo, a therapeutic specifically targeting Niemann-Pick Type C disease and Alzheimer's disease. Charles E. Rick Strattan founded the company on August 9, 1990, and it is presently based in Gainesville, Florida.
AD
